IP Library › Granted Patent US 12,383,494
Granted Patent B2
US 12,383,494 · App. 18/252,674 · Granted Aug 12, 2025

Packaging for rapidly infusing composition

Inventors: Simon Winslow (Ewing, NJ); Vincent T. Mileto (Flemington, NJ)
Assignee: ORCOSA, INC.
A61K9/006A61K9/0053A61K9/08A61K9/145A61K9/146A61K9/19A61K9/2063A61K31/05A61K31/4045A61K31/465A61K31/496A61K31/519A61K31/592A61K31/593A61K31/658A61K45/06A61K47/10A61K47/26A61K47/42A61K47/46A61P23/00A61P25/08A61P25/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,383,494
App. No.
18/252,674
Granted
Aug 12, 2025
Kind
B2
Abstract

A container for a lyophilized rapidly infusing composition is described. The container comprises a planar lidding layer attached to a well layer comprising pockets for the therapeutic product. The lidding layer may comprise an aluminum layer, a thermoplastic polymer layer, and a labeling layer. The well layer may comprise an aluminum layer, two polyamide layers, and two thermoplastic polymer layers. A drug product assembly is also disclosed, which includes at least one therapeutic product sealed within the at least one pocket of the container.

Claims (54)

1. A container for a therapeutic product, comprising:

a substantially planar lidding layer, and

a well layer,

wherein the lidding layer comprises, in order from an exterior lid side to an interior lid side:

a labeling layer;

a thermoplastic polymer lidding layer; and

an aluminum lidding layer:

wherein the interior lid side is removably attached to an interior well side,

wherein the well layer is shaped to form one or more pockets between the interior lid side and the interior well side, each pocket configured to enclose the therapeutic product,

wherein the one or more pockets each comprise a substantially flat portion in the center of the pocket and the substantially flat portion of the one or more pockets is connected to the top of the pocket by a sidewall comprising two or more sections, wherein a lower section of the sidewall exhibits a greater degree of concavity than an upper section of the sidewall, and

wherein the well layer comprises, in order from the interior well side to an exterior well side:

a first thermoplastic polymer well layer;

a first polyamide layer;

an aluminum well layer;

a second polyamide layer; and

a second thermoplastic polymer well layer.

2. The container of claim 1 , wherein the lidding layer and/or the well layer further comprise adhesive interlayers.

3. The container of claim 1 , wherein the lidding layer and the well layer each independently have:

a moisture vapor transmission rate of less than 0.05 g/m 2 /day measured at 38° C. and 90% relative humidity, and/or

an oxygen transmission rate of less than 0.01 mL/m 2 /day measured at 23° C. and 50% relative humidity.

4. The container of claim 1 , wherein the lidding layer further comprises a lacquer layer at the interior lid side.

5. The container of claim 1 , wherein the thermoplastic polymer lidding layer, the first thermoplastic polymer well layer, and the second thermoplastic polymer well layer each independently comprise at least one polymer selected from the group consisting of polyvinylchloride, polyethylene terephthalate, polyamide, polyethylene, poly(lactic-co-glycolic acid), polytetrafluoroethylene, polyvinylidene fluoride, polylactic acid, polypropylene, polystyrene, polyvinyl acetate, and polyvinylidene chloride.

6. The container of claim 5 , wherein the first and second thermoplastic polymer well layers consist essentially of polyvinylchloride.

7. The container of claim 1 , wherein the first and second polyamide layers comprise oriented polyamide.

8. The container of claim 1 , wherein the labeling layer comprises paper.

9. The container of claim 1 , wherein the lidding layer has an average layer thickness in a range of 90-130 μm, and

wherein the well layer has an average layer thickness in a range of 190-300 μm.

10. The container of claim 1 , having one or more edges or corners where the lidding laver and the well layer are not attached to each other.

11. The container of claim 1 , wherein the one or more pockets includes at least two pockets, and

wherein the lidding layer and the well layer have a perforated line between the at least two pockets.

12. The container of claim 1 , wherein the one or more pockets includes at least three pockets separated by at least two perforated lines, and

wherein each adjacent two perforations are spaced by a distance in a range of 20-50 mm.

13. The container of claim 1 , wherein the lidding layer and/or the well layer are knurled where the interior lid side is removably attached to the interior well side of the well layer.

14. The container of claim 1 , wherein the one or more pockets are each rotationally symmetric about a central axis and have a non-convex cross-sectional profile.

15. The container of claim 1 , wherein the substantially flat portion in the center of the pocket includes a raised or lowered portion(s) to deboss or emboss a logo or other information into the therapeutic product.

16. The container of claim 1 , wherein the one or more pockets each has a volume in a range of 0.3-4.0 cm 3 .

17. The container of claim 1 , wherein the one or more pockets each has a vertical depth in a range of 3-10 mm.

18. The container of claim 1 , wherein the lower section of the sidewall and the upper section of the sidewall each comprises a plurality of planar faces.

19. The container of claim 18 , wherein the substantially flat portion in the center of the pocket is octagonal in shape.

20. A drug product container assembly, comprising:

the container of claim 1 , and

at least one therapeutic product in the at least one pocket,

wherein the at least one therapeutic product is a rapidly infusing composition.

21. The drug product container assembly of claim 20 , wherein the rapidly infusing composition has a disintegration time of approximately 1 to 30 seconds in deionized water maintained at 37° C.±2° C.

22. The drug product container assembly of claim 20 , wherein the rapidly infusing composition has a disintegration time of approximately 1 to 5 seconds in deionized water maintained at 37° C.±2° C.

23. The drug product container assembly of claim 20 , wherein the rapidly infusing composition comprises a pharmaceutically acceptable binder and/or excipient system comprising gelatin and a sugar alcohol.

24. The drug product container assembly of claim 23 , wherein the sugar alcohol comprises mannitol.

25. The drug product container assembly of claim 20 , wherein the rapidly infusing composition is lyophilized.

26. The drug product container assembly of claim 20 , wherein the rapidly infusing composition comprises a therapeutically effective amount of cannabidiol or a derivative/analog thereof.

27. The drug product container assembly of claim 26 , wherein the rapidly infusing composition comprises a therapeutically effective amount of cannabidiol.

28. The drug product container assembly of claim 25 , wherein the rapidly infusing composition comprises a therapeutically effective amount of a derivative/analog of cannabidiol.

29. The drug product container assembly of claim 27 wherein the derivative/analog of cannabidiol is cannabidiolic acid methyl ester.

30. The container of claim 15 , wherein the substantially flat portion in the center of the pocket comprises a raised portion forming an identifiable feature.

31. The container of claim 15 , wherein the substantially flat portion in the center of the pocket comprises a depressed portion forming an identifiable feature.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2025
From: WINSLOW, SIMON; MILETO, VINCENT T.
To: ORCOSA INC.
Reel/Frame 071680/0566 →
Continuity (10)
Continuation 17225738 · Apr 8, 2021
Provisional Application 63180193 · Apr 27, 2021
Provisional Application 63172343 · Apr 8, 2021
Provisional Application 63172386 · Apr 8, 2021
Provisional Application 63172362 · Apr 8, 2021
Provisional Application 63172368 · Apr 8, 2021
Provisional Application 63147453 · Feb 9, 2021
Provisional Application 63114194 · Nov 16, 2020
Provisional Application 63114181 · Nov 16, 2020
Related Publication 20240009129A1 · Jan 11, 2024
References Cited (255)
US 3894896A · Watanabe · 1975 [cited by examiner]
US 5110007A · Law · 1992 [cited by examiner]
US 5112616A · McCarty · 1992 [cited by applicant]
US 5343672A · Kearney · 1994 [cited by examiner]
US 5457895A · Thompson · 1995 [cited by examiner]
US 5631023A · Kearney et al. · 1997 [cited by applicant]
US 5720974A · Makino et al. · 1998 [cited by applicant]
US 5729958A · Kearney et al. · 1998 [cited by applicant]
US 6007824A · Duckett et al. · 1999 [cited by applicant]
US 6307346B1 · Downer et al. · 2001 [cited by applicant]
US 6316027B1 · Johnson et al. · 2001 [cited by applicant]
US 6316029B1 · Jain et al. · 2001 [cited by applicant]
US 6391237B1 · Kearney et al. · 2002 [cited by applicant]
US 6509040B1 · Murray et al. · 2003 [cited by applicant]
US 6534094B2 · Moyano et al. · 2003 [cited by applicant]
US 6709669B1 · Murray et al. · 2004 [cited by applicant]
US 6830153B2 · French · 2004 [cited by examiner]
US 6860405B1 · Poynter · 2005 [cited by applicant]
US 7090866B2 · Johnson et al. · 2006 [cited by applicant]
US 7135180B2 · Truong-Le · 2006 [cited by applicant]
US 7331460B2 · Barndt et al. · 2008 [cited by applicant]
US 7360652B2 · Arnold · 2008 [cited by applicant]
US 7393674B2 · Jiang et al. · 2008 [cited by applicant]
US 7395928B2 · Bertsch · 2008 [cited by examiner]
US 7464818B2 · Gherdan et al. · 2008 [cited by applicant]
US 7607834B2 · Alvater et al. · 2009 [cited by applicant]
US 7758936B2 · Spallek · 2010 [cited by examiner]
US 7771745B2 · Wang et al. · 2010 [cited by applicant]
US 7799860B2 · Sugishita et al. · 2010 [cited by applicant]
US 7951397B2 · Dietrich et al. · 2011 [cited by applicant]
US 7968594B2 · Guy et al. · 2011 [cited by applicant]
US 7972621B2 · Wong et al. · 2011 [cited by applicant]
US 8268354B2 · Truong-Le et al. · 2012 [cited by applicant]
US 8445524B2 · Courvoisier et al. · 2013 [cited by applicant]
US 8545836B2 · Kaul et al. · 2013 [cited by applicant]
US 8545879B2 · Burns et al. · 2013 [cited by applicant]
US 8598207B2 · Buehler · 2013 [cited by applicant]
US 8647668B2 · Tanaka et al. · 2014 [cited by applicant]
US 8722366B2 · Sasaki et al. · 2014 [cited by applicant]
US 8802145B2 · Bauer · 2014 [cited by applicant]
US 8865722B2 · Hrakovsky et al. · 2014 [cited by applicant]
US 8946153B2 · Gupta et al. · 2015 [cited by applicant]
US 8974824B2 · Amminabavi et al. · 2015 [cited by applicant]
US 9066870B2 · Hu et al. · 2015 [cited by applicant]
US 9119794B2 · Middlbeek et al. · 2015 [cited by applicant]
US 9241902B2 · Rowe et al. · 2016 [cited by applicant]
US 9265764B2 · Haggarty et al. · 2016 [cited by applicant]
US 9408879B2 · Guglielmetti et al. · 2016 [cited by applicant]
US 9415015B2 · Jacobi et al. · 2016 [cited by applicant]
US 9468679B2 · Debunne et al. · 2016 [cited by applicant]
US 9492379B2 · Park et al. · 2016 [cited by applicant]
US 9629920B2 · Leighton et al. · 2017 [cited by applicant]
US 9717681B2 · Banbury et al. · 2017 [cited by applicant]
US 9717684B2 · Bhavsar et al. · 2017 [cited by applicant]
US 9717692B2 · Bilgic · 2017 [cited by applicant]
US 9731018B2 · Ahuja et al. · 2017 [cited by applicant]
US 9775819B2 · Bahl et al. · 2017 [cited by applicant]
US 9808521B2 · Weigandt et al. · 2017 [cited by applicant]
US 9820937B2 · Brewer et al. · 2017 [cited by applicant]
US 9833408B1 · Greenspoon · 2017 [cited by applicant]
US 9839613B2 · Qiao et al. · 2017 [cited by applicant]
US 9872873B2 · Khattar et al. · 2018 [cited by applicant]
US 9895342B2 · Maione et al. · 2018 [cited by applicant]
US 9901603B2 · Borody · 2018 [cited by applicant]
US 9956169B2 · Tian et al. · 2018 [cited by applicant]
US 9963265B1 · Braverman · 2018 [cited by examiner]
US 9974826B2 · Klein et al. · 2018 [cited by applicant]
US 9980915B2 · Matsuoka et al. · 2018 [cited by applicant]
US 10064849B2 · Ridall et al. · 2018 [cited by applicant]
US 10086078B2 · Ahuja et al. · 2018 [cited by applicant]
US 10137167B2 · Klein et al. · 2018 [cited by applicant]
US 10226525B2 · Anderson et al. · 2019 [cited by applicant]
US 10307394B2 · Chistov · 2019 [cited by applicant]
US 10307397B2 · Allen et al. · 2019 [cited by applicant]
US 10307459B2 · Nilsson et al. · 2019 [cited by applicant]
US 10383911B2 · Abels et al. · 2019 [cited by applicant]
US 10420809B2 · Crowley · 2019 [cited by applicant]
US 10548839B2 · Tian · 2020 [cited by applicant]
US 10604467B2 · Emanuele et al. · 2020 [cited by applicant]
US 10617650B2 · Bhambhani et al. · 2020 [cited by applicant]
US 10624940B2 · Speier · 2020 [cited by applicant]
US 10632164B2 · Schaneville · 2020 [cited by applicant]
US 10695332B2 · Ridall et al. · 2020 [cited by applicant]
US 10799467B2 · Whalley et al. · 2020 [cited by applicant]
US 10888518B2 · Jaspart et al. · 2021 [cited by applicant]
US 10888519B2 · Soni et al. · 2021 [cited by applicant]
US 10905681B2 · Wrobel et al. · 2021 [cited by applicant]
US 10925853B2 · Bruun et al. · 2021 [cited by applicant]
US 10928829B2 · Tatourian et al. · 2021 [cited by applicant]
US 10973766B2 · Pillay et al. · 2021 [cited by applicant]
US 10988638B2 · Wong et al. · 2021 [cited by applicant]
US 11000480B2 · Deshpande et al. · 2021 [cited by applicant]
US 12043463B1 · Braverman · 2024 [cited by examiner]
US D1062448S · Washington · 2025 [cited by examiner]
US 20030017209A1 · Parikh et al. · 2003 [cited by applicant]
US 20030229027A1 · Eissens et al. · 2003 [cited by applicant]
US 20040023948A1 · Green et al. · 2004 [cited by applicant]
US 20040076666A1 · Green et al. · 2004 [cited by applicant]
US 20040156894A1 · Grother et al. · 2004 [cited by applicant]
US 20050042177A1 · Ryde et al. · 2005 [cited by applicant]
US 20060093679A1 · Mayer et al. · 2006 [cited by applicant]
US 20060134195A1 · Fu et al. · 2006 [cited by applicant]
US 20060138016A1 · Harper · 2006 [cited by examiner]
US 20070122355A1 · Monteith et al. · 2007 [cited by applicant]
US 20070134493A1 · Meghpara · 2007 [cited by applicant]
US 20070259857A1 · Gray · 2007 [cited by applicant]
US 20070298090A1 · Chen et al. · 2007 [cited by applicant]
US 20080200452A1 · Obermeier et al. · 2008 [cited by applicant]
US 20080213343A1 · Obermeier et al. · 2008 [cited by applicant]
US 20080251411A1 · Walker · 2008 [cited by examiner]
US 20080305168A1 · Moon et al. · 2008 [cited by applicant]
US 20090226522A1 · Howes et al. · 2009 [cited by applicant]
US 20090308780A1 · Nonomura · 2009 [cited by examiner]
US 20100239646A1 · Nair · 2010 [cited by applicant]
US 20110097395A1 · Babul et al. · 2011 [cited by applicant]
US 20110217313A1 · Becker et al. · 2011 [cited by applicant]
US 20110268809A1 · Brinkley et al. · 2011 [cited by applicant]
US 20120118788A1 · Stevens · 2012 [cited by examiner]
US 20120165413A1 · Fujiwara et al. · 2012 [cited by applicant]
US 20130015095A1 · Carson · 2013 [cited by examiner]
US 20130039981A1 · Cherurkuri · 2013 [cited by applicant]
US 20140079756A1 · Andersen et al. · 2014 [cited by applicant]
US 20150096920A1 · Trombley · 2015 [cited by examiner]
US 20150133504A1 · Ridall et al. · 2015 [cited by applicant]
US 20150191288A1 · Jolley · 2015 [cited by examiner]
US 20160015683A1 · McCarty · 2016 [cited by applicant]
US 20160058866A1 · Sekura et al. · 2016 [cited by applicant]
US 20160159541A1 · Brandl · 2016 [cited by applicant]
US 20160243055A1 · Yeshurun · 2016 [cited by applicant]
US 20170112762A1 · Sivert et al. · 2017 [cited by applicant]
US 20170295817A1 · Rojano Jorge et al. · 2017 [cited by applicant]
US 20170319433A1 · Hosoi · 2017 [cited by examiner]
US 20170326147A1 · Sa et al. · 2017 [cited by applicant]
US 20170348249A1 · Negre et al. · 2017 [cited by applicant]
US 20180064645A1 · Greenspoon · 2018 [cited by applicant]
US 20180092853A1 · Hassan et al. · 2018 [cited by applicant]
US 20180110810A1 · Sadowsky et al. · 2018 [cited by applicant]
US 20180153794A1 · Coric et al. · 2018 [cited by applicant]
US 20180169022A1 · Jaspart et al. · 2018 [cited by applicant]
US 20180279641A1 · Dong · 2018 [cited by applicant]
US 20180311205A1 · Morgan · 2018 [cited by applicant]
US 20180369221A1 · Ridall et al. · 2018 [cited by applicant]
US 20190008848A1 · Zhang et al. · 2019 [cited by applicant]
US 20190008870A1 · Chen · 2019 [cited by applicant]
US 20190070124A1 · Anavi-Goffer · 2019 [cited by applicant]
US 20190083391A1 · Bond · 2019 [cited by applicant]
US 20190083611A1 · Yi · 2019 [cited by applicant]
US 20190307675A1 · Rosenbaum et al. · 2019 [cited by applicant]
US 20190314274A1 · Masto et al. · 2019 [cited by applicant]
US 20190314368A1 · Liang et al. · 2019 [cited by applicant]
US 20190328673A1 · Wan et al. · 2019 [cited by applicant]
US 20190388392A1 · Ahmed et al. · 2019 [cited by applicant]
US 20200009232A1 · Fuhrherr et al. · 2020 [cited by applicant]
US 20200022945A1 · Swartout · 2020 [cited by applicant]
US 20200022993A1 · Zhong et al. · 2020 [cited by applicant]
US 20200054563A1 · Li et al. · 2020 [cited by applicant]
US 20200061138A1 · Williams · 2020 [cited by applicant]
US 20200115317A1 · Mechoulam et al. · 2020 [cited by applicant]
US 20200138704A1 · Wan et al. · 2020 [cited by applicant]
US 20200138721A1 · Grother et al. · 2020 [cited by applicant]
US 20200138730A1 · Madwar et al. · 2020 [cited by applicant]
US 20200170933A1 · Wong et al. · 2020 [cited by applicant]
US 20200190215A1 · Schwaeble et al. · 2020 [cited by applicant]
US 20200197364A1 · Prud'Homme et al. · 2020 [cited by applicant]
US 20200222402A1 · Purohit et al. · 2020 [cited by applicant]
US 20200222529A1 · Zhang · 2020 [cited by applicant]
US 20200237733A1 · Geissler et al. · 2020 [cited by applicant]
US 20200253875A1 · Coffman et al. · 2020 [cited by applicant]
US 20200268667A1 · McLaughlin et al. · 2020 [cited by applicant]
US 20200268668A1 · McLaughlin et al. · 2020 [cited by applicant]
US 20200268676A1 · McLaughlin et al. · 2020 [cited by applicant]
US 20200268677A1 · McLaughlin et al. · 2020 [cited by applicant]
US 20200269546A1 · Fogtmann · 2020 [cited by examiner]
US 20200316025A1 · Sreedharala et al. · 2020 [cited by applicant]
US 20200330423A1 · Brunn et al. · 2020 [cited by applicant]
US 20200330425A1 · Bruun et al. · 2020 [cited by applicant]
US 20200368197A1 · Donaduzzi et al. · 2020 [cited by applicant]
US 20200383969A1 · Coric et al. · 2020 [cited by applicant]
US 20200390704A1 · McLaughlin et al. · 2020 [cited by applicant]
US 20210000814A1 · Coric et al. · 2021 [cited by applicant]
US 20210008191A1 · Conlan et al. · 2021 [cited by applicant]
US 20210267934A1 · Macphail et al. · 2021 [cited by applicant]
US 20220151934A1 · Ridall et al. · 2022 [cited by applicant]
US 20240082107A1 · Laugros · 2024 [cited by examiner]
AU 2019379706A1 · 2021 [cited by applicant]
CN 1320887C · 2007 [cited by applicant]
EP 1171134A1 · 2002 [cited by applicant]
EP 1780005A1 · 2007 [cited by applicant]
EP 1787800A1 · 2007 [cited by applicant]
EP 2722036A1 · 2014 [cited by applicant]
EP 2428202B1 · 2015 [cited by applicant]
EP 3479822A1 · 2019 [cited by applicant]
GB 1548022 · 1979 [cited by applicant]
JP 2017155049 · 2017 [cited by applicant]
WO WO0054777A1 · 2000 [cited by applicant]
WO WO2019042247A1 · 2000 [cited by applicant]
WO WO2013165468A1 · 2013 [cited by applicant]
WO WO2016014454A1 · 2016 [cited by applicant]
WO WO2018082814A1 · 2018 [cited by applicant]
WO WO2018222923A1 · 2018 [cited by applicant]
WO WO2019153064A1 · 2019 [cited by applicant]
WO WO2019219773A1 · 2019 [cited by applicant]
WO WO2019231225A1 · 2019 [cited by applicant]
WO WO2019231865A1 · 2019 [cited by applicant]
WO WO2019232783A1 · 2019 [cited by applicant]
WO WO2020024011A1 · 2020 [cited by applicant]
WO WO2020037152A1 · 2020 [cited by applicant]
WO WO2020051371A2 · 2020 [cited by applicant]
WO WO2020061584A1 · 2020 [cited by applicant]
WO WO2020098774A1 · 2020 [cited by applicant]
WO WO2020121326A1 · 2020 [cited by applicant]
WO WO2020146753A1 · 2020 [cited by applicant]
WO WO2020165407A1 · 2020 [cited by applicant]
WO WO2020171727A2 · 2020 [cited by applicant]
WO 2020185214A1 · 2020 [cited by applicant]
WO WO2020186010A1 · 2020 [cited by applicant]
WO WO2020188568A1 · 2020 [cited by applicant]
International Search Report and Written Opinion issued Jan. 28, 2022 in PCT/US21/58045 filed Nov. 4, 2021, 5 pages. [cited by applicant]
International Search Report and Written Opinion issued Jan. 31, 2022 in PCT/US21/58061 filed Nov. 4, 2021, 8 pages. [cited by applicant]
International Search Report and Written Opinion issued Feb. 4, 2022 in PCT/US21/59184 filed Nov. 12, 2021, 8 pages. [cited by applicant]
International Search Report and Written Opinion issued Feb. 8, 2022 in PCT/US21/59088 filed Nov. 12, 2021, 12 pages. [cited by applicant]
International Search Report and Written Opinion issued Feb. 1, 2022 in PCT/US21/57938 filed Nov. 3, 2021, 8 pages. [cited by applicant]
International Search Report and Written Opinion issued Jan. 31, 2022 in PCT/US21/57901 filed Nov. 3, 2021, 10 pages. [cited by applicant]
International Search Report and Written Opinion issued Feb. 10, 2022 in PCT/US21/58038 filed Nov. 4, 2021, 12 pages. [cited by applicant]
International Search Report and Written Opinion issued Jan. 31, 2022 in PCT/US21/57931 filed Nov. 3, 2021, 8 pages. [cited by applicant]
International Search Report and Written Opinion issued Feb. 16, 2022 in PCT/US21/57917 filed Nov. 3, 2021, 10 pages. [cited by applicant]
International Search Report and Written Opinion issued Mar. 10, 2022 in PCT/US21/059140 filed Nov. 12, 2021, 10 pages. [cited by applicant]
International Search Report and Written Opinion issued Mar. 8, 2022 in PCT/US21/057915 filed Nov. 3, 2021, 12 pages. [cited by applicant]
Kasteler et al. “Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis,” Journal of the American Academy of Dermatolo… [cited by applicant]
Baghdadi, “Effect of methotrexate use on the development of type 2 diabetes in rheumatoid arthritis patients: A systematic review and meta-analysis.” PLOS One, vol. 15(7):e0235637. Jul. 6, 2020 (Jul. 6, 2020) [Retrieved… [cited by applicant]
“Why Do I Need Folic Acid When I'm Taking Methotrexate?” (Evans) Oct. 8, 2020 (Oct. 8, 2020), [Retrieved on Jan. 10, 2022], Retrieved from <URL:https://www.goodrx.com/methotrexate/why-do-i-need-folic-acid-when-taking- m… [cited by applicant]
“Gelatin vs. Veggie Capsules & CBD” , Millie, Oct. 9, 2020, 4 pages, Retrieved from <URL: https://millie.co/blogs/cbd/gelatin-vs-veggie-capsules-cbd>. [cited by applicant]
Chandrasekhar et al., “The role of formulation excipients in the development of lyophilised fast-disintegrating tablets”, European Journal of Pharmaceutics and Biopharmaceutics, vol. 72 Issue 1 (Dec. 3, 2008): pp. 119-1… [cited by applicant]
Augusto dos Santos Garcia et al., “Gelatin/starch orally disintegrating films as a promising system for vitamin C delivery”, Food Hydrocolloids, vol. 79 (2018): pp. 127-135. [cited by applicant]
Seager H, “Drug-delivery Products and the Zydis Fast-dissolving Dosage Form”, J Pharm Pharmacol, 1998, 50, pp. 375-382. [cited by applicant]
Damle B et al., “Pharmacokinetics of a Novel Orodispersible Tablet of Sildenafil in Healthy Subjects”, Clinical Therapeutics, vol. 36, No. 2, 2014, pp. 236-244. [cited by applicant]
Zhu et al., “An evaluation of anti-hyperalgesic effects of cannabidiolic acid-methyl ester in a preclinical model of peripheral neuropathic pain”, British Journal of Pharmacology, vol. 177, pp. 2712-2725. (Year: 2020). [cited by applicant]
Lu et al., “An Introduction to the Endogenous Cannabinoid System”, Biological Psychiatry, 2016, 36 pages. [cited by applicant]
Guindon et al., “The endocannabinoid system and pain”, CNS Neurol Disord Drug Targets, 2009; 8 (6), 39 pages. [cited by applicant]
Bergamaschi et al., “Safety and side effects of cannabidiol, a Cannabis sativa constituent”, Current Drug Safety, 2011; 6, pp. 237-249. [cited by applicant]
Iffland et al., “An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies”, Cannabis and Cannabinoid Research, (2017) 2:1, pp. 139-154. [cited by applicant]
Zhornitsky et al., “Cannabidiol in humans-the quest for therapeutic targets”, Pharmaceuticals, 2012; 5(5), pp. 529-552. [cited by applicant]
Parker et al., “Regulation of nausea and vomiting by cannabinoids”, British Journal of Pharmacology, 2011; 163(7), pp. 1411-1422. [cited by applicant]
“Tablet,” Stedman's Medical Dictionary (1972), 22nd ed, p. 1250. [cited by applicant]
“Tablet,” Stedman's Medical Dictionary (1990), 25th ed, pp. 1549-1550. [cited by applicant]
“Tablet,” Stedman's Medical Dictionary (1995), 26th ed, pp. 1757-1758. [cited by applicant]
“Tablet,” Stedman's Medical Dictionary (2006), 28th ed, pp. 1930-1931. [cited by applicant]
Hu, S. et al. “A mussel-inspired film for adhesion to wet buccal tissue and efficient buccal drug delivery,” Nature Communications, 12:1689 (2021). [cited by applicant]
Alaia et al., “Buccally Absorbed Cannabidiol Shows Significantly Superior Pain Control and Improved Satisfaction Immediately After Rotator Cuff Repair,” The American Journal of Sports Medicine 1-8 (2022). [cited by applicant]
Notcutt, W. et al., “Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 'N of 1′ studies,” Anaesthesia, 2004, 59, pp. 440-452. [cited by applicant]
Millar, S.A. et al., “A systematic review of cannabidiol dosing in clinical populations,” British Journal of Clinical Pharmacology, 2019, 85, pp. 1888-1900. [cited by applicant]
Abilify FDA Label, Otsuka Pharmaceutical Co., Ltd., 2014. [cited by applicant]
Epidiolex FDA label, Greenwich Biosciences, Inc., 2021. [cited by applicant]
Ward et al., Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1 Areceptors without diminishing nervous system function of chemotherapy efficacy, Oct. 4, 2013, British Journal of Pharmacology, vol. 17… [cited by applicant]
European Search Report dated Oct. 21, 2024 re EP Application No. 21892604.6. [cited by applicant]